Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay.

Proceedings of the National Academy of Sciences of the United States of America·2018
Same author

Frontotemporal dementia.

Handbook of clinical neurology·2018
Same author

Increased subjective experience of non-target emotions in patients with frontotemporal dementia and Alzheimer's disease.

Current opinion in behavioral sciences·2018
Same author

Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration.

Neurology·2018
Same author

The Longitudinal Trajectory of Default Mode Network Connectivity in Healthy Older Adults Varies As a Function of Age and Is Associated with Changes in Episodic Memory and Processing Speed.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2018
Same author

Downregulation of exosomal miR-204-5p and miR-632 as a biomarker for FTD: a GENFI study.

Journal of neurology, neurosurgery, and psychiatry·2018
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Manizhe Eslami-Amirabadi1,2,3, Tara N Ellingson4, Melanie Stephens4

  • 1University of California, San Francisco, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

粉样蛋白PET扫描可以提高痴呆症诊断的准确性. 然而,负面扫描显示了对LATE和脑血管疾病等疾病的更好的生物标志物的需求,特别是在75岁以上的患者中.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 医疗成像医学成像
  • 老年病的医生 老年病的医生

背景情况:

  • 与病理确认相比,阿尔茨海默病 (AD) 的临床诊断存在局限性.
  • 粉样蛋白PET成像不侵入性检测粉样蛋白斑块,一个关键的AD生物标志物,提高诊断准确度和临床决策.
  • 粉胺PET的医疗保险覆盖率增加,导致其在痴呆患者护理中得到更广泛的利用.

研究的目的:

  • 在现实世界痴呆症诊断环境中审查粉样蛋白PET扫描的利用.
  • 分析粉胺PET对痴呆症患者差异诊断的影响.
  • 了解负粉样蛋白PET扫描的诊断影响.

主要方法:

  • 记忆和衰老中心1708名患者遭遇的回顾性图表审查 (2023年7月至2024年7月).
  • 包括547名患有痴呆症生物标志物测试订单 (PET和液体生物标志物) 的独特患者的920次接触.
  • 对接受粉样蛋白PET治疗的患者的评估差异诊断和成像发现,与其他痴呆症综合征的诊断标准进行比较.

主要成果:

  • 在43%的遭遇中订购了amyloid PET,但在24%的订购中没有执行.
  • 接受粉样蛋白PET治疗的患者中有24%的扫描结果为阴性.
  • 阴性PET扫描的诊断包括边缘主导性与年龄相关的TDP蛋白质病变 (LATE),脑血管疾病,勒维体病,4R形病变和功能/精神疾病,通常有多种促成因素,特别是在75岁以上的患者中.

结论:

  • 粉样蛋白PET对于识别符合粉样蛋白向治疗的患者至关重要,但负面结果会导致诊断不确定性,特别是在非专业的环境中.
  • 伦理方面的考虑来自于在没有粉样蛋白病理的患者中诊断的不确定性.
  • 为替代性神经病理诊断开发可靠的生物标志物对于减少不确定性和改善对非阿尔茨海默氏症痴呆症的护理至关重要.